ArticleCancer chemotherapy and pharmacology2026
Adverse events of cetuximab sarotalocan in photoimmunotherapy: insights from the Japanese adverse drug event report database.
Article in Cancer chemotherapy and pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
purposeCetuximab sarotalocan is an innovative photoimmunotherapy agent for cancer treatment, with an unclear safety profile. We analysed the clinical adverse event profile of cetuximab sarotalocan in photoimmunotherapy.
methodsIn this retrospective study, we analysed real-world clinical data of patients with head and neck cancer from the Japanese Adverse Drug Event Report database. Patient demographics, as well as the nature of adverse events and their outcomes and co-occurrences, were analysed.
resultsCetuximab sarotalocan adverse event reports (n = 227) predominantly included older male patients. The most frequent adverse event was laryngeal oedema, followed by upper respiratory and oral complications. Recovery rates were high for laryngeal oedema and tongue-related adverse events but poor for fistula-related complications. Co-occurrence was found between different adverse events, particularly laryngeal oedema and dysphagia.
conclusionThe described safety profile of cetuximab sarotalocan in photoimmunotherapy offers insights for its proper use as well as baseline data for the development and improvement of cancer photoimmunotherapy.
Indexed as
Identifiers
42581129What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.